Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 0 4 IN DEXTROSE 5 IN PLASTIC CONTAINER versus LIDOPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 0 4 IN DEXTROSE 5 IN PLASTIC CONTAINER versus LIDOPEN.
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER vs LIDOPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is a sodium channel blocker that inhibits depolarization of cardiac myocytes and nerve axons by binding to voltage-gated sodium channels and stabilizing the neuronal membrane, thereby preventing the propagation of action potentials.
Lidocaine is a sodium channel blocker, stabilizing neuronal membranes by inhibiting the influx of sodium ions, thereby preventing the propagation of action potentials and producing local anesthesia.
Intravenous infusion: 1-4 mg/min (20-50 mcg/kg/min) for cardiac arrhythmias. Bolus: 1-1.5 mg/kg IV, then infusion.
Lidocaine 2% topical gel: Apply 1-2 grams (approximately 5-10 cm ribbon) to affected area every 4-6 hours as needed, not to exceed 5 grams per day. For infiltration anesthesia: 1% solution, 0.5-5 mL injected locally; maximum 4.5 mg/kg.
None Documented
None Documented
Terminal elimination half-life approximately 1.5-2 hours after bolus, prolonged to 2-4 hours in heart failure or hepatic impairment; continuous infusion may show context-sensitive half-life.
1.5–2 hours (terminal); prolonged in hepatic impairment
Renal excretion of unchanged drug and metabolites; <10% unchanged in urine, >90% as metabolites (primarily monoethylglycinexylidide and glycinexylidide). Biliary/fecal elimination minimal (<1%).
Renal (10% unchanged; 80% as metabolites), biliary/fecal (10%)
Category A/B
Category C
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic